Protembis: Funding, Investors & Team (Sep 2026)
The goal of ProtEmbo is to provide a straightforward and dependable solution for preventing a common complication during TAVR procedures. Transcatheter treatments have revolutionized care for patients unable to undergo traditional open heart surgery due to disabilities or other health issues. Despite advancements in TAVR techniques, cerebrovascular events remain a significant concern. Protembis was established with the aim of reducing this risk and improving outcomes, particularly as TAVR becomes more common in younger and healthier patients. The ProtEmbo System is a device used alongside TAVR to capture and divert any embolic material away from the brain, ultimately making the procedure safer.
Protembis has raised $54.3M across 2 funding rounds on record, the most recent an undisclosed round of $21.7M announced in Jul 2024.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Protembis Company Profile and Key Stats
Latest funding round on record: Jul 2024.
Protembis Funding Rounds
Protembis raised $32.6M in an undisclosed round announced in Mar 2024.
4 months later, an undisclosed round of $21.7M was announced in Jul 2024.
Protembis Founders and Leadership Team
No contact details are on record for this team yet.
Protembis Funding Compared to Other Biotechnology Startups
Protembis' latest round of $21.7M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Protembis in Biotechnology and Aachen
Companies Similar to Protembis
Computomics applies AI to bioinformatics data to enable rapid understanding of genomics and drive advanced…
smartbax develop novel multi-targeted, antibacterial compounds with extraordinary potency against multi-drug…
Pacifico Biolabs offers fermentation biotechnology for development, production and distribution of…
NanoStruct is a biotechnology company that develops nanostructured sensor chips to identify bacteria and…
Tacalyx, a company originating from Max-Planck-Institute of Colloids and Interfaces in Potsdam, Germany, is…
Primogene is a biotechnology company that provides ingredient development, bioprocess manufacturing, and…
Mbiomics is a company in the field of biotechnology.
At EVANIUM, we make plant compounds like polyphenols and flavonoids more effective by improving their…
Picea Biosolutions is a biotechnology firm. Based on their core platform technology, they develop tailored…
KUPANDO is a pioneering biopharmaceutical firm that is developing TLR 4/7 agonists to boost innate immunity.…
Protembis Funding FAQs
What does Protembis do?
The goal of ProtEmbo is to provide a straightforward and dependable solution for preventing a common complication during TAVR procedures. Transcatheter treatments have revolutionized care for patients unable to undergo traditional open heart surgery due to disabilities or other health issues. Despite advancements in TAVR techniques, cerebrovascular events remain a significant concern. Protembis was established with the aim of reducing this risk and improving outcomes, particularly as TAVR becomes more common in younger and healthier patients. The ProtEmbo System is a device used alongside TAVR to capture and divert any embolic material away from the brain, ultimately making the procedure safer.
How much funding has Protembis raised?
Protembis has raised $54.3M across 2 rounds on record. The most recent is an undisclosed round of $21.7M announced in Jul 2024.
When did Protembis last raise funding?
Protembis' most recent funding round on record is an undisclosed round of $21.7M, announced in Jul 2024.
Who founded Protembis?
FundedIQ lists Conrad Rasmus (Founder), Karl Von Mangoldt (Founder) at Protembis.
Where is Protembis headquartered?
Protembis is based in Aachen, Nordrhein-Westfalen, Germany.
How many employees does Protembis have?
Protembis is in the 11-50 employee band.
How does Protembis' funding compare to other Biotechnology startups?
Protembis' latest round of $21.7M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Protembis Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Protembis is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.